P
Peter Chiba
Researcher at Medical University of Vienna
Publications - 65
Citations - 1901
Peter Chiba is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: ATP-binding cassette transporter & Transmembrane domain. The author has an hindex of 25, co-authored 65 publications receiving 1717 citations. Previous affiliations of Peter Chiba include University of Vienna.
Papers
More filters
Journal ArticleDOI
P-glycoprotein substrate binding domains are located at the transmembrane domain/transmembrane domain interfaces: a combined photoaffinity labeling-protein homology modeling approach.
Karin Pleban,Stephan Kopp,Edina Csaszar,Michael Peer,Thomas Hrebicek,Andreas Rizzi,Gerhard F. Ecker,Peter Chiba +7 more
TL;DR: A set of propafenonetype substrate photoaffinity ligands has been used in this study in conjunction with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry to define the substrate binding domain(s) of P-gp in more detail, and binding at domain interfaces may be a general feature of polyspecific drug efflux pumps.
Journal ArticleDOI
Nanoparticle delivery of anticancer drugs overcomes multidrug resistance in breast cancer.
TL;DR: This review will mainly focus on MDR-associated proteins, as well as various nanoparticle formulations developed to overcome MDR in breast cancer.
Journal ArticleDOI
Remodeling the regulation of iron metabolism during erythroid differentiation to ensure efficient heme biosynthesis
Matthias Schranzhofer,Manfred Schifrer,Javier Antonio Cabrera,Stephan Kopp,Peter Chiba,Hartmut Beug,Ernst W. Müllner +6 more
TL;DR: Mass cultures of primary murine erythroid progenitors from fetal liver suggest that highly efficient utilization of iron in mitochondrial heme synthesis during normal erythropoiesis alters the regulation of iron metabolism via the IRE/IRP system.
Journal ArticleDOI
Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24).
Petra Heffeter,Michael A. Jakupec,Wilfried Körner,Peter Chiba,Christine Pirker,R. Dornetshuber,L. Elbling,Hedwig Sutterlüty,Michael Micksche,Bernhard K. Keppler,Walter Berger +10 more
TL;DR: KP772 is hyperactive in MDR cells and might have chemosensitizing properties by blocking ABCB1 expression, and the data suggest that KP772 should be especially active against notoriously drug-resistant tumor types and as second line treatment after standard chemotherapy failure.
Journal ArticleDOI
Structure–Activity Relationships, Ligand Efficiency, and Lipophilic Efficiency Profiles of Benzophenone-Type Inhibitors of the Multidrug Transporter P-Glycoprotein
TL;DR: Docking studies of selected analogues into a homology model of P-glycoprotein suggest that benzophenones show an interaction pattern similar to that previously identified for propafenone-type inhibitors.